human health

Immunization: great progresses and challenges

The World Health Organization (WHO) is celebrating the Immunization Week with the main goal of promoting vaccination to protect people at all ages from diseases. Since Jenner invented the first vaccine against smallpox at the end of XVIII century, the progresses in the prevention area have saved millions of lives worldwide and they will continue doing it in the future.

According to the WHO, immunization Immunization averts an estimated 2 to 3 million deaths every year from diphtheria, tentanus, whooping cough and measles. Other preventable diseases through vaccination are meningitis, hepatitis B, mumps, poliomyelitis and rubella, among others. Although the immunization coverage is higher and higher in the world, there are still a lot of challenges to achieve. The same institution shows that around 18.7 million of breast-fed babies worldwide in 2014 were not covered by the system of vaccination, because of that it is necessary to double efforts.

Further information about immunization coverage (WHO)

Vaccination is one of the mainstays of the preventive medicine, being the flagship for Medicine at the XXI century. Immunization is a broad field of scientific research for human and animal health. Bionaturis, an international benchmark in the development of biologic vaccines for both sectors, is working in this sphere of knowledge. With the main goal of putting ultimate health technologies and products at a more global reach of customers and users, Bionaturis has developed its alternative platform to produce biological products, FLYLIFE, that offers flexibility, high scale-up speed and less demand of space and investment. Bionaturis has a rich portfolio of biologic products as a vaccine against visceral canine leishmaniosis, another one against nematodes in livestock and other vaccines that prevent several diseases in birds, swines and fish in aquaculture. About human health, the […]

April 26th, 2016|Blog english|Comments Off|

Bionaturis unveils the development of six new biotech products

Five of these new drugs point to Animal Health sector that represents a $100 billion global annual worldwide market

According to “Global Animal Healthcare Market Size, Share, Development, Growth and Demand Forecast to 2020” report (by  P&S Market Research) around $29 billion were assigned to pharmaceutical products, feed additives and vaccines in 2014.

The same report forecasts for this segment up to $44 billion by 2020, with a CAGR of 7.0%

The population growth and standard of living, resulting on a higher consumption of milk and meat and an increasing trend of adopting pets are some of the main robust drivers for the growth of the Animal Health market, which has nowadays a booming demand on both biological products and compounds devoted to reduce the use of traditional antibiotics

Broadening its portfolio Bionaturis Group strengthens its position as a reference partner to develop biological products for animal health from livestock to pets, having presence in the main markets at geographic, species and diseases level

 

Jerez de la Frontera, October 6th 2015. Bionaturis Group (ticker BNT) has recently unveiled up to six new biotech developments broadening its products portfolio, now accounting for more than twenty compounds in different developing stages for both human and animal health.

Five of these new products are devoted to veterinarian sector, pointing to several high-relevance diseases in livestock and pets, such as atopic dermatitis, osteoarthritis (or arthrosis) and different types of cancer, enhancing the Group position as a benchmark partner in the development of biological products for animal health.

The new unveiled products are:

Lead

Description

Indication

Specie

Stage

BNT014
Tailored universal VLP-vaccine
Prevention of common cold (rhinovirus)
Humans
Proof of concept in vivo

BNT015
Recombinant VPL Vaccine
Viral infection
Swine
Proof of concept in vivo

BNT018
Recombinant VPL Vaccine
Rabbit Hemorrhagic Fever
Rabits
Proof of concept in vivo

BNT020
Feline recombinant interferon omega (bio-better)
Antiviral, antiproliferative, immunomodulatory
Dogs and cats
Proof […]

October 6th, 2015|Blog english, Press Releases|Comments Off|

Bionaturis summits a new patent application

The new patent intends to protect a new antimicrobial peptide, Garvicin A, which has shown high specificity against lactococcosis.
Lactococcosis is an emerging disease caused by bacteria, which affects several fish species and causes important economic losses in the aquaculture sector, among others.
The pathogen, having the greater economic impact in the farming trout, affects not just Spain but also other countries of the Mediterranean Basin.
The bacteria have been also isolated from human clinical episodes associated with severe infections and even septicemia.
The new antimicrobial compound can be used to combat the current problems of resistance and specificity facing the industry.

Bionaturis -BNT-MAB-, a leading global company in biological drugs development, and the Complutense University -Madrid- (UCM), have summited a joint patent application intended to protect a new antimicrobial peptide, Garvicin A. The invention provides a new compound and its corresponding formulations to be used as a high-specific antimicrobial product against Lactococcus garvieae, a pathogen bacteria affecting industrial sectors such as the dairy industry or trout fish farming, causing important economic losses annually.
 The novel peptide, not described so far, has shown promising specific in-vitro antibacterial activity. “The use of this unique bacteriocin could lead to a real alternative solution to prevent and treat lactococcosis, meaning a great saving to affected producers”, stated Alicia Gibello, main researcher at UCM.
Javier Gallastegui, the company’s managing director added: “we have chosen this product because its specificity, being able to use it to prevent and treat lactococcosis in living organisms without affecting the natural biota balance of the body. Besides, it’s an alternative over conventional antibiotics where the problem of resistance is an issue of major concerns of global health authorities”. Thus, the biotech company adds a new product to its portfolio of […]

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.

CERRAR